WWFHTX

WWFHTX is a grassroots initiative that unites health consumers, biopharmaceutical company employees vendors, suppliers, academic and community partners.

[WWFHTX @WWFHTX]

The prescription drug supply chain, including #PBMs, is now making more money off of those #medicines than the #biopharma companies that developed them. https://t.co/rOP8XYNOvY @txhbi From: Berkeley Research Group #BRG

[WWFHTX @WWFHTX]

“What was meant to be a patient-focused program is now a hospital markup program where large, tax-exempt hospital systems buy discounted drugs, mark them up by as much as 1,000% or more and bill patients and insurers the list price.” #340B #340BReform https://t.co/c21Fu4MjMM

[WWFHTX @WWFHTX]

.@wendellpotter testifies to TX lawmakers: “. . . something is deeply broken when [#healthinsurance] coverage keeps getting more expensive while care becomes harder to access. . .” @txhbi https://t.co/6ntNaEehKh

[WWFHTX @WWFHTX]

Per @sallypipes of @PacificResearch, with so little federal oversight, some hospitals are using the #340B program as an unchecked profit stream. @txhbi https://t.co/tB4FjEVLki

[WWFHTX @WWFHTX]

Learn more about why four out of five Texans support #340BReform to stop abuse of the #340B program. @BioNorthTX https://t.co/qTUxAmMBrv

[WWFHTX @WWFHTX]

Read what whistleblower and former VP of Cigna, @wendellpotter, had to say to TX lawmakers about #healthinsurance reform. #EndInsuranceAbuse @Stopafib https://t.co/6ntNaEehKh

[WWFHTX @WWFHTX]

Three in four surveyed adults are concerned hospitals benefiting from #340B drug discounts pursue aggressive debt collection practices against patients. #340BReform @TXDisabilities https://t.co/yWJvjULyXM

[WWFHTX @WWFHTX]

Per @AdapAdvocacy, #340B has become a cash cow for its providers, with many large hospital systems abusing this program, costing patients. #340BReform @txhbi https://t.co/9CTvRoTB7y

[WWFHTX @WWFHTX]

A lack of transparency in the #340B program provides fertile ground for waste, fraud and abuse. #340BReform is needed. @IAFAccess https://t.co/iiBovvA4Hp

[WWFHTX @WWFHTX]

The practices of both middlemen #PBMs and #healthinsurance companies directly contribute to the high out-of-pocket costs patients are forced to pay. https://t.co/4qxsyfrh1H

[WWFHTX @WWFHTX]

Dr. Robert Popovian of @GHLForg on #340BReform: “Hospitals taking in hundreds of millions of dollars, if not billions, in #340B-related revenue, should have to show how that money is actually helping patients.” @TCCRI https://t.co/GlkmfA2DUR

[WWFHTX @WWFHTX]

Learn more about the Lone Star State’s continued growth and leadership in #biopharma R&D, growth and innovation. #Texas @BioNorthTX https://t.co/Elz3R1MOtc

[WWFHTX @WWFHTX]

How #pricecontrols on drugs reduce the incentive to invest in risky research, resulting in fewer new drugs, fewer cures and fewer lives saved. @txhbi https://t.co/k6r5B1fZNr

[WWFHTX @WWFHTX]

Read how #healthinsurance companies have raised premiums, cut benefits, narrowed provider networks & shed members deemed too costly to cover – all at the expense of patients. #EndInsuranceAbuse @Stopafib https://t.co/lDKhCdIauX

[WWFHTX @WWFHTX]

.@MerrillMatthews says #healthinsurance giants must lower costs by restoring competition, increasing transparency & putting patients back in control. #InsuranceReform @Protectaxpayers https://t.co/sNPLKymKzl

[WWFHTX @WWFHTX]

“As it stands currently, model estimates issued by the White House on cost savings from #MFN prices are highly speculative and depend on a set of unrealistic assumptions.” #MostFavoredNation @NTxCommission https://t.co/85o7Lml2uE

[WWFHTX @WWFHTX]

Leading policy experts examine abuse in the federal #340B program and the urgent need for #340Breform. @TXDisabilities https://t.co/TJ9WQ2fReL

[WWFHTX @WWFHTX]

.@ASCO issues new policy statement/recommendations for needed #340BReform measures to address accountability in the #340B program. @IAFaccess https://t.co/xPqiYMYuYn

[WWFHTX @WWFHTX]

Federal judge reveals how the #340B hospital markup program fleeces drug manufacturers and patients. #340BReform https://t.co/KS4OnEPAwR

[We Work For Health @weworkforhealth]

Policies intended to accelerate access can undermine innovation if they weaken the intellectual property systems that sustain drug development in the first place. Henry Hadad of @bmsnews examines how recent EU IP reforms could reshape investment decisions and ultimately limit patient access to future therapies: https://t.co/tWZJM44wN0

[We Work For Health @weworkforhealth]

New Jersey is home to one of the world's leading life sciences hubs – supporting hundreds of thousands of jobs and fueling billions in economic activity. MFN pricing puts this all at risk and would limit patient access to medicines, reduce R&D investment, and slow the next generation of cures.

More from WWFH’s @DLeonard_DC and @ChrissyButeas of @HINJ_ORG: https://t.co/DKYg96YeXP